Back to Stakeholders

Clexio Biosciences is a private Israeli clinical-stage CNS company founded in 2018 by Teva Pharmaceuticals R&D veterans. Their lead programme CLE-100 is a once-daily oral tablet formulation of esketamine for MDD — distinguished from the FDA-approved Spravato (intranasal, in-clinic) by enabling outpatient, at-home use. Phase 2 CLEO study results showed a promising safety profile and encouraging efficacy specifically in post-COVID MDD subgroups; the Phase 2 SOLEO study (NCT06340958, higher dose, stricter treatment-resistance criteria) enrolled first patients April 2024 and reached 50% enrollment by December 2024. CLE-100 holds multiple US method-of-use patents (2024). In December 2025, Clexio spun out its muscarinic agonist programme (CLE-905) into a new entity, Syremis Therapeutics, which raised $165M Series A co-led by Dexcel Pharma and Third Rock Ventures. Co-founders Kogan, Levy, and Kagan simultaneously lead Syremis; Clexio continues independently with CLE-100 and preclinical CLE-043.

Development Programmes

2

CLE-100 (Oral Esketamine)

Esketamine
Phase II

Major depressive disorder (inadequate antidepressant response)

Programme Tracker

Major Depressive Disorder (MDD)

Primary: US (FDA)
Phase IIActive

SOLEO Phase 2 (NCT06340958) enrolling at US sites; oral esketamine once daily x4 weeks in patients with inadequate response to ≥2 antidepressants

Milestones

Phase II started

Completed

Actual: Jun 1, 2024

SOLEO Phase 2 (NCT06340958) initiated; oral esketamine adjunct to antidepressants; US multi-centre

Why it matters: SOLEO is designed to generate registration-enabling efficacy data for oral esketamine as an adjunct to standard antidepressants — the same patient population as Spravato but with the convenience of oral dosing. Success would address the major commercial limitation of intranasal esketamine (clinic-only administration).

Watch next: SOLEO primary endpoint results (HAM-D change from baseline at 4 weeks)

Phase II topline

Completed

Actual: Oct 1, 2023

CLEO Phase 2 (NCT04103892) results presented at ASCP: 130 subjects randomised across 32 US sites; safety profile confirmed; post-acute COVID subgroup showed promising efficacy signal

Why it matters: CLE-100 is an oral esketamine (S-ketamine) formulation designed for once-daily home dosing — bypassing the intranasal/IV administration burden of Spravato. CLEO safety data enables the SOLEO Phase 2b with a larger sample and primary efficacy endpoint.

Recorded Events

Jun 1, 2024: Phase II started

Oct 1, 2023: Phase II topline

Evidence Links

CLE-905 (M1/M4 Muscarinic Agonist)

Phase I

Schizophrenia

Programme Tracker

Schizophrenia

Primary: US (FDA)
Phase IActive

Licensed to Syremis Therapeutics (spinout, Q2 2024); Syremis raised $165M Series A (Dec 2025); Phase 1 underway under Syremis as ST-905; Clexio retains internal development rights

Milestones

Licensing deal

Completed

Actual: Jun 1, 2024

CLE-905 spun out to Syremis Therapeutics (Q2 2024); renamed ST-905 at Syremis

Why it matters: CLE-905 is a potent dual M1/M4 preferential muscarinic agonist for schizophrenia — the same validated mechanism as KarXT/Cobenfy (FDA-approved 2024). Syremis was founded by former Karuna Therapeutics team members (who developed KarXT), giving ST-905/CLE-905 the highest-possible team pedigree for this mechanism.

Funding milestone

Completed

Actual: Dec 1, 2025

Syremis Therapeutics raises $165M Series A (December 2025)

Why it matters: $165M Series A led by former Karuna leadership validates ST-905's potential to compete with or improve upon KarXT in the schizophrenia market. Clexio retains value from this spinout through equity/milestone payments.

Watch next: Syremis Phase 1 FIH results for ST-905; Clexio CLE-905 internal Phase 1 timeline

Recorded Events

Dec 1, 2025: Funding milestone

Jun 1, 2024: Licensing deal

Evidence Links

Quick Facts

Type
Private Biotech
Lead Stage
Phase II
Website
Visit

Sponsored Trials

1